Role of glycosphingolipids in HIV-1 entry: requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Role of glycosphingolipids in HIV-1 entry: requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion.

Biosci Rep. 1999 Aug;19(4):317-25. Unique Identifier : AIDSLINE MED/20055942
Puri A; Hug P; Jernigan K; Rose P; Blumenthal R; Section of Membrane Structure and Function, LECB, Division of; Basic Sciences, National Cancer Institute, National Institutes of; Health, Frederick, MD 21702-1201, USA. apuri@helix.nih.gov

Abstract: We have recently shown that addition of human erythrocyte glycosphingolipids (GSL) to non-human CD4+ or GSL-depleted human CD4+ cells rendered those cells susceptible to gp120-gp41-mediated cell fusion (Puri et al., BBRC, 1998). One GSL fraction (Fraction 3) isolated from human erythrocyte GSL mixture exhibited the highest recovery of fusion following incorporation into CD4+ non-human and GSL-depleted HeLa-CD4 cells (HeLa-CD4/GSL-). Structural analysis of Fraction 3 showed that this GSL had identical head group as the known GSL, Gal(alpha1-->4)Gal(beta1-->4)Glc-Ceramide (Gb3) (Puri et al., PNAS, 1998). Here we report that presence of Gb3 in CD4+/CXCR4+ cells but not CD4+/CXCR4 cells allows fusion with HIV-1Lai-envelope glycoprotein expressing cells (TF228). Therefore, Gb3 functions in conjunction with HIV-1 co-receptor, CXCR4 to promote fusion. We propose that Gb3 functions by recruiting CD4 and/or CXCR4 at the fusion site through structurally specific interactions.

Keywords: JOURNAL ARTICLE Antigens, CD4/*METABOLISM Carbohydrate Sequence Cell Fusion Chromatography, Thin Layer CD4-Positive T-Lymphocytes/VIROLOGY Erythrocytes/VIROLOGY Glycosphingolipids/*METABOLISM Hela Cells Human HIV-1/*METABOLISM Models, Biological Molecular Sequence Data Receptors, CXCR4/*METABOLISM Support, U.S. Gov't, P.H.S. Trihexosylceramides/*METABOLISM Tumor Cells, Cultured Viral Fusion Proteins/*METABOLISM

KWDjournalarticleantigens,cd4/KWDmetabolismcarbohydratesequencecellfusionchromatography,thinlayercd4-positivet-lymphocytes/virologyerythrocytes/virologyglycosphingolipids/KWDmetabolismhelacellshumanhiv-1/KWDmetabolismmodels,biologicalmolecularsequencedatareceptors,cxcr4/KWDmetabolismsupport,uKWDsKWDgov't,pKWDhKWDsKWDtrihexosylceramides/KWDmetabolismtumorcells,culturedviralfusionproteins/KWDmetabolism
000430
A0040933

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .